References:
[1] Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960. DOI:10.1001/jama.2020.4006.
[2] Zhou S, Yao Z. Roles of Infection in Psoriasis. INT J MOL SCI. 2022;23(13). DOI:10.3390/ijms23136955.
[3] Shah H, Busquets AC. Psoriasis Flares in Patients With COVID-19 Infection or Vaccination: A Case Series. Cureus. 2022;14(6):e25987. DOI:10.7759/cureus.25987.
[4] Zeng H, Wang S, Chen L, et al. Biologics for Psoriasis During the COVID-19 Pandemic. Frontiers in medicine. 2021;8:759568. DOI:10.3389/fmed.2021.759568.
[5] Liu M, Wang H, Liu L, et al. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis. FRONT IMMUNOL. 2022;13:1046352. DOI:10.3389/fimmu.2022.1046352.
[6] Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. ANNU REV IMMUNOL. 2014;32:227-255. DOI:10.1146/annurev-immunol-032713-120225.